Theratechnologies Stock Price, News & Analysis (TSE:TH)

C$8.07 0.12 (1.51 %)
(As of 01/19/2018 07:37 AM ET)
Previous CloseC$7.95
Today's RangeC$7.94 - C$8.10
52-Week RangeC$2.95 - C$8.72
Volume45,997 shs
Average Volume99,201 shs
Market CapitalizationC$604.94 million
P/E Ratio-42.47
Dividend YieldN/A
Beta0.8

About Theratechnologies (TSE:TH)

Theratechnologies logoTheratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

Receive TH News and Ratings via Email

Sign-up to receive the latest news and ratings for TH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:TH
CUSIPN/A
Phone+1-514-3367800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-42.4736842105263
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.19)
Net IncomeN/A
Net Margins-25.69%
Return on Equity-25.45%
Return on Assets-15.56%

Miscellaneous

EmployeesN/A
Outstanding Shares74,923,000

Theratechnologies (TSE:TH) Frequently Asked Questions

What is Theratechnologies' stock symbol?

Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc (TSE:TH) issued its earnings results on Tuesday, July, 14th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The firm had revenue of $7.08 million for the quarter, compared to the consensus estimate of $6.45 million. Theratechnologies had a negative return on equity of 25.45% and a negative net margin of 25.69%. View Theratechnologies' Earnings History.

When will Theratechnologies make its next earnings announcement?

Theratechnologies is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Theratechnologies.

Where is Theratechnologies' stock going? Where will Theratechnologies' stock price be in 2018?

3 equities research analysts have issued 12 month price objectives for Theratechnologies' stock. Their forecasts range from C$7.50 to C$9.25. On average, they anticipate Theratechnologies' share price to reach C$8.50 in the next year. View Analyst Ratings for Theratechnologies.

Who are some of Theratechnologies' key competitors?

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the folowing people:

  • Dawn A Svoronos, Independent Chairman of the Board (Age 63)
  • Luc Tanguay, President, Chief Executive Officer, Director (Age 57)
  • Philippe Dubuc, Chief Financial Officer, Senior Vice President
  • Lyne Fortin, Senior Vice President, Chief Commercial Officer
  • Christian Marsolais Ph.D., Senior Vice President - Scientific Affairs and Alliances (Age 52)
  • Marie-Noel Colussi, Vice President - Finance (Age 46)
  • Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary (Age 48)
  • Pierre Perazzelli, Vice President - Pharmaceutical Development (Age 63)
  • Dale Weil, Director
  • Gilles Cloutier Ph.D., Independent Director (Age 70)

How do I buy Theratechnologies stock?

Shares of Theratechnologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Theratechnologies' stock price today?

One share of Theratechnologies stock can currently be purchased for approximately C$8.07.

How big of a company is Theratechnologies?

Theratechnologies has a market capitalization of C$604.94 million.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.


MarketBeat Community Rating for Theratechnologies (TH)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Theratechnologies (TSE:TH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$8.50C$8.50C$8.83C$8.05
Price Target Upside: 15.96% upside15.96% upside12.38% upside2.90% downside

Theratechnologies (TSE:TH) Consensus Price Target History

Price Target History for Theratechnologies (TSE:TH)

Theratechnologies (TSE:TH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/14/2017National Bank FinancialLower Price TargetOutperformC$9.75 -> C$8.75View Rating Details
10/6/2017ScotiabankLower Price TargetOutperformC$10.00 -> C$9.25View Rating Details
5/5/2017Canaccord GenuityReiterated RatingSpeculative BuyC$7.50View Rating Details
7/6/2016MackieLower Price TargetC$5.30 -> C$4.40View Rating Details
(Data available from 1/19/2016 forward)

Earnings

Theratechnologies (TSE:TH) Earnings History and Estimates Chart

Earnings by Quarter for Theratechnologies (TSE:TH)

Theratechnologies (TSE TH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
10/5/2017Q3 2017C($0.03)C($0.04)ViewN/AView Earnings Details
7/12/2017Q2 2017C($0.03)C($0.13)ViewN/AView Earnings Details
4/6/2017Q1 2017C($0.01)C($0.03)ViewN/AView Earnings Details
10/4/2016Q3 2016C$0.01C$0.01ViewN/AView Earnings Details
7/5/2016Q2 2016C$0.02C($0.01)ViewN/AView Earnings Details
2/24/2016Q4 2015C$0.03C$0.01ViewN/AView Earnings Details
10/1/2015Q3 2015C$0.02ViewN/AView Earnings Details
7/14/2015Q2C($0.02)C$0.01C$6.45 millionC$7.08 millionViewListenView Earnings Details
4/14/2015Q1 2015C($0.03)C($0.01)ViewN/AView Earnings Details
2/26/2015Q4 2014C($0.09)C($0.06)ViewN/AView Earnings Details
10/8/2014Q3 2014C($0.07)ViewN/AView Earnings Details
7/9/2014Q2 2014C$0.02ViewN/AView Earnings Details
4/14/2014Q1 2014C($0.06)ViewN/AView Earnings Details
2/27/2014Q4 2013C($0.04)ViewN/AView Earnings Details
10/10/2013Q3 2013C($0.03)ViewN/AView Earnings Details
7/10/2013Q2 2013C($0.02)ViewN/AView Earnings Details
2/27/2013Q4 2012C($0.02)ViewN/AView Earnings Details
10/11/2012Q3 2012C($0.02)C($0.01)ViewN/AView Earnings Details
7/12/2012Q2 2012C($0.02)C($0.02)ViewN/AView Earnings Details
4/13/2012Q1 2012C($0.07)C($0.06)ViewN/AView Earnings Details
2/8/2012Q4 2011C($0.07)C($0.03)ViewN/AView Earnings Details
10/13/2011Q3 2011C($0.08)C($0.06)ViewN/AView Earnings Details
7/7/2011Q2 2011C($0.06)C($0.10)ViewN/AView Earnings Details
4/12/2011Q1 2011C($0.04)C($0.10)ViewN/AView Earnings Details
10/12/2010Q3 2010C($0.09)C($0.08)ViewN/AView Earnings Details
7/7/2010Q2 2010C($0.07)C($0.11)ViewN/AView Earnings Details
3/23/2010Q1 2010C($0.09)C($0.07)ViewN/AView Earnings Details
2/10/2010Q4 2009C($0.09)C($0.11)ViewN/AView Earnings Details
10/5/2009Q3 2009C($0.07)C($0.11)ViewN/AView Earnings Details
7/7/2009Q2 2009C($0.12)C($0.09)ViewN/AView Earnings Details
2/9/2009Q4 2008C$0.32C($0.17)ViewN/AView Earnings Details
7/9/2008Q2 2008C($0.20)ViewN/AView Earnings Details
3/25/2008Q1 2008C($0.20)C($0.20)ViewN/AView Earnings Details
1/23/2008Q4 2007C($0.12)C($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Theratechnologies (TSE:TH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Theratechnologies (TSE:TH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Theratechnologies (TSE TH) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Theratechnologies (TSE:TH)

Theratechnologies (TSE TH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Luc TanguayDirectorBuy2,300C$6.64C$15,272.00
11/15/2017Philippe DubucInsiderBuy1,000C$6.66C$6,660.00
7/18/2017Christian MarsolaisInsiderBuy3,000C$7.12C$21,360.00
7/17/2017Philippe DubucInsiderBuy1,000C$8.00C$8,000.00
5/24/2017Philippe DubucInsiderBuy600C$6.42C$3,852.00
4/7/2017Philippe DubucInsiderBuy400C$5.89C$2,356.00
7/7/2016G�Rald A LacosteDirectorBuy4,000C$2.36C$9,440.00
4/8/2016Philippe DubucInsiderBuy3,300C$2.00C$6,600.00
4/7/2016Pierre PerazzelliDirectorSell7,700C$1.95C$15,015.00
4/6/2016Pierre PerazzelliDirectorSell6,500C$0.38C$2,470.00
4/5/2016Marie-No�L ColussiInsiderSell10,000C$2.04C$20,384.00
4/5/2016Pierre PerazzelliDirectorSell6,500C$2.05C$13,325.00
6/26/2015G�Rald A LacosteDirectorBuy10,000C$1.47C$14,700.00
5/22/2015Paul PommierDirectorBuy20,300C$1.40C$28,420.00
5/21/2015Paul PommierDirectorBuy25,000C$1.38C$34,500.00
5/5/2015Dawn SvoronosDirectorBuy5,000C$1.26C$6,300.00
5/1/2015Lyne FortinInsiderBuy9,900C$1.23C$12,177.00
4/30/2015Luc TanguayDirectorBuy4,100C$1.19C$4,879.00
(Data available from 1/1/2013 forward)

Headlines

Theratechnologies (TSE TH) News Headlines

Source:
DateHeadline
Theratechnologies, Inc. breached its 50 day moving average in a Bullish Manner : TH-CA : December 29, 2017Theratechnologies, Inc. breached its 50 day moving average in a Bullish Manner : TH-CA : December 29, 2017
finance.yahoo.com - December 29 at 7:40 AM
Brokers Set Expectations for Theratechnologies Inc.s FY2018 Earnings (TH)Brokers Set Expectations for Theratechnologies Inc.'s FY2018 Earnings (TH)
www.americanbankingnews.com - November 18 at 8:52 AM
Theratechnologies Inc. (TH) Director Luc Tanguay Purchases 2,300 SharesTheratechnologies Inc. (TH) Director Luc Tanguay Purchases 2,300 Shares
www.americanbankingnews.com - November 15 at 9:59 PM
Theratechnologies, Inc. – Value Analysis (TORONTO:TH) : November 14, 2017Theratechnologies, Inc. – Value Analysis (TORONTO:TH) : November 14, 2017
finance.yahoo.com - November 15 at 2:43 PM
Theratechnologies Inc. (TH) Price Target Cut to C$8.75Theratechnologies Inc. (TH) Price Target Cut to C$8.75
www.americanbankingnews.com - November 14 at 2:28 PM
Theratechnologies, Inc. breached its 50 day moving average in a Bearish Manner : TH-CA : November 13, 2017Theratechnologies, Inc. breached its 50 day moving average in a Bearish Manner : TH-CA : November 13, 2017
finance.yahoo.com - November 14 at 9:36 AM
Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
finance.yahoo.com - November 14 at 9:36 AM
Calculating The Fair Value Of Theratechnologies Inc (TSX:TH)Calculating The Fair Value Of Theratechnologies Inc (TSX:TH)
finance.yahoo.com - November 5 at 7:05 AM
Theratechnologies, Inc. breached its 50 day moving average in a Bearish Manner : TH-CA : October 27, 2017Theratechnologies, Inc. breached its 50 day moving average in a Bearish Manner : TH-CA : October 27, 2017
finance.yahoo.com - October 27 at 4:21 PM
Daily Coverage on Healthcare Stocks, Concordia International, ProMetic Life Sciences, Theratechnologies and Cardiome PharmaDaily Coverage on Healthcare Stocks, Concordia International, ProMetic Life Sciences, Theratechnologies and Cardiome Pharma
finance.yahoo.com - October 23 at 8:15 AM
Theratechnologies, Inc. :TH-CA: Earnings Analysis: Q3, 2017 By the Numbers : October 9, 2017Theratechnologies, Inc. :TH-CA: Earnings Analysis: Q3, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 10 at 7:26 AM
Research Analysts Set Expectations for Theratechnologies Incs FY2018 Earnings (TH)Research Analysts Set Expectations for Theratechnologies Inc's FY2018 Earnings (TH)
www.americanbankingnews.com - October 9 at 6:22 AM
Theratechnologies Inc (TH) Rating Increased to Outperform Market Weight at National Bank FinancialTheratechnologies Inc (TH) Rating Increased to Outperform Market Weight at National Bank Financial
www.americanbankingnews.com - October 7 at 6:36 AM
Scotiabank Lowers Theratechnologies Inc (TH) Price Target to C$9.25Scotiabank Lowers Theratechnologies Inc (TH) Price Target to C$9.25
www.americanbankingnews.com - October 6 at 1:46 PM
Theratechnologies Inc (TH) Given New C$9.75 Price Target at National Bank FinancialTheratechnologies Inc (TH) Given New C$9.75 Price Target at National Bank Financial
www.americanbankingnews.com - October 6 at 1:44 PM
Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™ - PR Newswire (press release)Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™ - PR Newswire (press release)
www.prnewswire.com - October 6 at 11:17 AM
Theratechnologies Announces Financial Results for Third Quarter of 2017Theratechnologies Announces Financial Results for Third Quarter of 2017
finance.yahoo.com - October 6 at 11:17 AM
Theratechnologies reports 3Q lossTheratechnologies reports 3Q loss
finance.yahoo.com - October 6 at 11:17 AM
Edited Transcript of TH.TO earnings conference call or presentation 5-Oct-17 12:30pm GMTEdited Transcript of TH.TO earnings conference call or presentation 5-Oct-17 12:30pm GMT
finance.yahoo.com - October 6 at 11:17 AM
Equities Analysts Issue Forecasts for Theratechnologies Incs Q3 2017 Earnings (TH)Equities Analysts Issue Forecasts for Theratechnologies Inc's Q3 2017 Earnings (TH)
www.americanbankingnews.com - October 6 at 7:14 AM
Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017(TM)Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017(TM)
finance.yahoo.com - October 4 at 10:06 AM
Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™
finance.yahoo.com - October 4 at 10:06 AM
Theratechnologies to Announce Financial Results for the Third Quarter of 2017Theratechnologies to Announce Financial Results for the Third Quarter of 2017
finance.yahoo.com - October 3 at 1:30 PM
Todays Research Reports on Theratechnologies, Aphria, Aurinia Pharmaceuticals and Theralase TechnologiesToday's Research Reports on Theratechnologies, Aphria, Aurinia Pharmaceuticals and Theralase Technologies
finance.yahoo.com - October 3 at 1:30 PM
Theratechnologies Inc (TH) Scheduled to Post Quarterly Earnings on ThursdayTheratechnologies Inc (TH) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - September 28 at 1:04 AM
Ibalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San DiegoIbalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San Diego
finance.yahoo.com - September 19 at 8:25 AM
5 Biotech Innovators Set To Excel In 20175 Biotech Innovators Set To Excel In 2017
www.baystreet.ca - September 14 at 11:16 AM
Biotech Breakthroughs: 5 Stocks To Watch In 2017Biotech Breakthroughs: 5 Stocks To Watch In 2017
www.baystreet.ca - September 12 at 10:57 AM
Canadian Healthcare Stocks Under Review, Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome PharmaCanadian Healthcare Stocks Under Review, Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma
finance.yahoo.com - August 17 at 8:17 AM
Edited Transcript of TH.TO earnings conference call or presentation 12-Jul-17 12:30pm GMTEdited Transcript of TH.TO earnings conference call or presentation 12-Jul-17 12:30pm GMT
finance.yahoo.com - August 14 at 6:16 AM
Theratechnologies Issues Reminder Regarding Warrant ExpiryTheratechnologies Issues Reminder Regarding Warrant Expiry
finance.yahoo.com - August 4 at 9:02 AM
Theratechnologies’ shares on upward trajectory as new drugs move closer to marketTheratechnologies’ shares on upward trajectory as new drugs move closer to market
www.theglobeandmail.com - August 3 at 7:54 AM
Theratechnologies, Inc. :TH-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017Theratechnologies, Inc. :TH-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017
finance.yahoo.com - August 3 at 7:54 AM
Theratechnologies Announces Completion of the Pre-License Inspection of the Ibalizumab Manufacturing FacilityTheratechnologies Announces Completion of the Pre-License Inspection of the Ibalizumab Manufacturing Facility
finance.yahoo.com - August 3 at 7:54 AM
Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)
finance.yahoo.com - July 25 at 7:30 AM
The Best Kept Secret Of The Marijuana BoomThe Best Kept Secret Of The Marijuana Boom
www.baystreet.ca - July 20 at 8:32 AM
Todays Research Reports on Theratechnologies Inc., VBI Vaccines Inc., Aralez Pharmaceuticals Inc. and Immunovaccine Inc.Today's Research Reports on Theratechnologies Inc., VBI Vaccines Inc., Aralez Pharmaceuticals Inc. and Immunovaccine Inc.
finance.yahoo.com - July 20 at 8:32 AM
Christian Marsolais Purchases 3,000 Shares of Theratechnologies Inc (TH) StockChristian Marsolais Purchases 3,000 Shares of Theratechnologies Inc (TH) Stock
www.americanbankingnews.com - July 19 at 1:15 PM
Theratechnologies to Announce Financial Results for the Second Quarter of 2017Theratechnologies to Announce Financial Results for the Second Quarter of 2017
finance.yahoo.com - July 6 at 12:53 PM
National Bank Financial Downgrades Theratechnologies Inc (TSE:TH) to Sector Perform Market WeightNational Bank Financial Downgrades Theratechnologies Inc (TSE:TH) to Sector Perform Market Weight
www.americanbankingnews.com - July 6 at 7:50 AM
FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral IbalizumabFDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
finance.yahoo.com - July 1 at 8:11 AM
Wall Street Analyst Gives This 180% Gainer Another 29% Upside: Time to Buy?Wall Street Analyst Gives This 180% Gainer Another 29% Upside: Time to Buy?
www.fool.ca - June 23 at 12:05 AM
Hydrogenics at 52-Week High on New ContractHydrogenics at 52-Week High on New Contract
www.baystreet.ca - June 8 at 3:50 PM
Amaya Hits 52-Week High on NewsAmaya Hits 52-Week High on News
www.baystreet.ca - May 12 at 3:41 PM
Futures up Slightly with Jobs Reports on HorizonFutures up Slightly with Jobs Reports on Horizon
www.baystreet.ca - May 5 at 9:02 AM
BRIEF-Theratechnologies Q1 loss per share C$0.03BRIEF-Theratechnologies Q1 loss per share C$0.03
www.reuters.com - April 7 at 12:58 PM
BRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territoriesBRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories
www.reuters.com - March 6 at 12:13 PM
Theratechnologies Strikes Deal, Hits 52-Week HighTheratechnologies Strikes Deal, Hits 52-Week High
www.baystreet.ca - March 6 at 12:13 PM
Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting ... - PR Newswire (press release)Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 6:29 AM
BRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III - ReutersBRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III - Reuters
www.reuters.com - January 18 at 12:20 AM

SEC Filings

Theratechnologies (TSE:TH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Theratechnologies (TSE TH) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.